1. Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells
- Author
-
Zhen Huang, Chunjiang Yu, Chunling Zhao, Bailin Zhang, Yongmei Song, Wei Zhou, Ling Ma, Yunwei Ou, Qimin Zhan, and Liying Ma
- Subjects
Cancer Research ,Esophageal Neoplasms ,Paclitaxel ,Cell Survival ,Morpholines ,Cyclin D ,Cyclin B ,Antineoplastic Agents ,Apoptosis ,Cyclin D1 ,Cell Line, Tumor ,medicine ,Humans ,PTEN ,Cyclin B1 ,RNA, Small Interfering ,PI3K/AKT/mTOR pathway ,Phosphoinositide-3 Kinase Inhibitors ,Cyclin ,Pharmacology ,Cisplatin ,biology ,PTEN Phosphohydrolase ,Molecular biology ,Proto-Oncogene Proteins c-bcl-2 ,Oncology ,Chromones ,Drug Resistance, Neoplasm ,Caspases ,Gene Knockdown Techniques ,Carcinoma, Squamous Cell ,Cancer research ,biology.protein ,Molecular Medicine ,Proto-Oncogene Proteins c-akt ,Research Paper ,Signal Transduction ,medicine.drug - Abstract
The role of cyclin B1 in the clinical therapeutic sensitivity of human esophageal squamous cell carcinoma (ESCC) remains to be defined. In this study, we found that elevated cyclin B1 expression attenuated the apoptosis induced by cisplatin or paclitaxel, while knockdown of cyclin B1 enhanced cisplatin or paclitaxel sensitivity in ESCC cells. Cyclin B1-mediated apoptosis may rely on the Bcl-2-dependent mitochondria-regulated intrinsic death pathway, and the antagonizing effect of cyclin B1 on chemotherapeutic agent-induced apoptosis was through PTEN/Akt pathway. Therefore, cyclin B1 might be a therapeutic target for the development of specific and efficient approaches in the treatment of ESCC.
- Published
- 2013
- Full Text
- View/download PDF